Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Petros Pharmaceuticals Inc PTPI

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment... see more

Recent & Breaking News (NDAQ:PTPI)

Petros Pharmaceuticals to Present at the Benzinga Healthcare Small Cap Conference

PR Newswire September 23, 2021

Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PR Newswire September 10, 2021

Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales

PR Newswire August 17, 2021

Petros Pharmaceuticals to Present at Two Upcoming August Conferences

PR Newswire August 12, 2021

Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit

Newsfile August 11, 2021

FDA Grants Meeting to Petros Pharmaceuticals to Discuss Label Expansion of Erectile Dysfunction Drug STENDRA®

PR Newswire July 27, 2021

Petros Pharmaceuticals Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment

PR Newswire July 13, 2021

Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021

PR Newswire July 12, 2021

Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021

PR Newswire June 2, 2021

Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales

PR Newswire May 17, 2021

Petros Pharmaceuticals to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021

PR Newswire May 14, 2021

Petros Pharmaceuticals to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021

PR Newswire May 7, 2021

Recently Published Research on Stendra®(avanafil) for Endothelial Function in Men with Erectile Dysfunction to Initiate Petros Pharmaceuticals' Plans for Expanded Labeling

PR Newswire March 18, 2021

Petros Pharmaceuticals Welcomes Dr. Mohit Khera to Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil)

PR Newswire February 18, 2021

Petros Pharmaceuticals Establishes Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil)

PR Newswire February 4, 2021

Petros Pharmaceuticals to Participate in NobleCon17

GlobeNewswire January 19, 2021

Neurotrope, Inc. Completes Independent Spin-off of Neurotrope Bioscience, Inc. and is Renamed Synaptogenix, Inc.

PR Newswire December 8, 2020